These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16096588)

  • 41. The role of ¹⁸F-FDG PET or ¹⁸F-FDG-PET/CT in the evaluation of solitary pulmonary nodules.
    Li W; Pang H; Liu Q; Zhou J
    Eur J Radiol; 2015 Oct; 84(10):2032-7. PubMed ID: 26094866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
    Balogova S; Huchet V; Kerrou K; Nataf V; Gutman F; Antoine M; Ruppert AM; Prignon A; Lavolée A; Montravers F; Mayaud C; Cadranel J; Talbot JN
    Nucl Med Commun; 2010 May; 31(5):389-97. PubMed ID: 20145579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity?
    Kim TJ; Park CM; Goo JM; Lee KW
    AJR Am J Roentgenol; 2012 Jan; 198(1):83-8. PubMed ID: 22194482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
    Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer.
    Gregory DL; Brennan SM; Stillie A; Herschtal A; Hicks RJ; MacManus MP; Ball DL
    J Med Imaging Radiat Oncol; 2010 Apr; 54(2):100-7. PubMed ID: 20518871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pulmonary mucosa-associated lymphoid tissue lymphoma: computed tomography and ¹⁸F fluorodeoxyglucose-positron emission tomography/computed tomography imaging findings and follow-up.
    Zhang WD; Guan YB; Li CX; Huang XB; Zhang FJ
    J Comput Assist Tomogr; 2011; 35(5):608-13. PubMed ID: 21926857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
    Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
    J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
    Van Laere K; Ceyssens S; Van Calenbergh F; de Groot T; Menten J; Flamen P; Bormans G; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):39-51. PubMed ID: 15309329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of positron-emission tomography with F18-fluorodeoxyglucose for the assessment of lung lesions suspicious of malignancy].
    Jofré MJ; Massardo T; González P; Canessa J; Sierralta P; Humeres P; Galaz R; Valdebenito R
    Rev Med Chil; 2005 May; 133(5):583-92. PubMed ID: 15970984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
    Metser U; Miller E; Lerman H; Even-Sapir E
    AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
    Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
    J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.